Get the Stockscreener App
253.44
3.74%
9.14
After Hours:
258.00
4.56
+1.80%
Alnylam Pharmaceuticals Inc stock is traded at $253.44, with a volume of 966.60K.
It is up +3.74% in the last 24 hours and up +1.17% over the past month.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
See More
Previous Close:
$244.30
Open:
$243.44
24h Volume:
966.60K
Relative Volume:
1.48
Market Cap:
$32.81B
Revenue:
$2.25B
Net Income/Loss:
$-278.16M
P/E Ratio:
-116.79
EPS:
-2.17
Net Cash Flow:
$-42.59M
1W Performance:
+4.54%
1M Performance:
+1.17%
6M Performance:
-8.28%
1Y Performance:
+71.05%
1-Day Range:
$243.44
$255.35
1-Week Range:
$239.02
$263.30
52-Week Range:
$141.97
$304.39
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Name
Alnylam Pharmaceuticals Inc
Sector
Industry
Phone
(617) 551-8200
Address
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
253.44 | 32.81B | 2.25B | -278.16M | -42.59M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
512.52 | 131.61B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.36 | 73.51B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
619.97 | 37.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ONC
Beigene Ltd Adr
|
266.26 | 28.62B | 3.81B | -644.79M | -669.77M | -6.24 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-12-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-16-24 | Upgrade | Goldman | Neutral → Buy |
| Feb-16-24 | Downgrade | Goldman | Buy → Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-08-23 | Initiated | Wells Fargo | Equal Weight |
| Oct-11-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| May-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-26-23 | Initiated | SMBC Nikko | Neutral |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Buy |
| Sep-09-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-27-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-07-22 | Initiated | William Blair | Outperform |
| Apr-25-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-01-22 | Initiated | Citigroup | Buy |
| Feb-03-22 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-22-21 | Upgrade | Goldman | Neutral → Buy |
| Nov-22-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-01-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-04-21 | Upgrade | UBS | Neutral → Buy |
| Aug-04-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-22-21 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-12-21 | Downgrade | Citigroup | Buy → Neutral |
| Feb-12-21 | Reiterated | H.C. Wainwright | Buy |
| Jan-25-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-30-20 | Resumed | Berenberg | Hold |
| Sep-08-20 | Initiated | Citigroup | Buy |
| Aug-11-20 | Downgrade | Oppenheimer | Outperform → Perform |
| May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
| May-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-24-20 | Resumed | Evercore ISI | Outperform |
| Mar-19-20 | Initiated | Berenberg | Buy |
| Dec-19-19 | Reiterated | Chardan Capital Markets | Buy |
| Nov-20-19 | Initiated | Oppenheimer | Outperform |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| May-23-19 | Resumed | Goldman | Neutral |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-06-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-05-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-23-19 | Initiated | UBS | Neutral |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-18 | Reiterated | Stifel | Buy |
| Aug-07-18 | Upgrade | Stifel | Hold → Buy |
| May-04-18 | Reiterated | Stifel | Hold |
| Mar-28-18 | Initiated | Evercore ISI | In-line |
View All
Alnylam Pharmaceuticals Inc Stock (ALNY) Latest News
Free genetic testing for AHP offered by Alnylam Act in US, Canada - Porphyria News
Alnylam at Stifel’s 2025 CNS Forum: Advances in RNAi for Neurological Diseases - Investing.com
Alnylam Pharmaceuticals To Present At Stifel 2025 Virtual CNS Forum; Webcast At 3:00 PM ET - Nasdaq
Arbor raises $74M amid genetic medicine’s funding slump - BioPharma Dive
RNA Therapies Clinical Trials and Pipeline 2025: EMA, PDMA, FDA Approvals, Medication, IND, NDA Approval, Therapies, Mechanism of Action, Route of Administration and Companies by DelveInsight - The Globe and Mail
How Do Investors Really Feel About Alnylam Pharmaceuticals? - Benzinga
Alnylam Rallies 62% in a Year: Can the Stock Maintain This Momentum? - Nasdaq
Alnylam Rallies 62% In A Year: Can The Stock Maintain This Momentum? - Barchart
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Victory Capital Management Inc. - Defense World
PreventionGenetics Assumes the Management of Sponsored Genetic Testing Program for Three Rare Genetic Diseases: Acute Hepatic Porphyria, Primary Hyperoxaluria Type 1 & Hereditary ATTR Amyloidosis - BioSpace
Antisense Oligonucleotides Market reached US$ 2,985.97 - openPR
Alnylam Pharmaceuticals’ SWOT analysis: strong data bolsters $8B amvuttra potential - Investing.com
Transthyretin Amyloidosis Treatment Market Is Booming - openPR
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $280.00 at JPMorgan Chase & Co. - Defense World
Demystifying Alnylam Pharmaceuticals: Insights From 15 Analyst Reviews - Benzinga
Alnylam Reveals Latest CNS Therapeutics Strategy at Upcoming Stifel Forum - StockTitan
Alnylam gearing up for Phase 3 trial of nucresiran in FAP late this year - FAP News Today
U.S. Transthyretin Amyloidosis Market Projected To Witness Substantial Growth, 2025-2032:Alnylam - EIN News
What is Zacks Research’s Estimate for ALNY Q1 Earnings? - Defense World
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Mutual of America Capital Management LLC - Defense World
FY2027 Earnings Forecast for ALNY Issued By Zacks Research - Defense World
Oppenheimer & Co. Inc. Has $404,000 Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Defense World
(ALNY) Proactive Strategies - Stock Traders Daily
Alnylam Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Purchased by IFP Advisors Inc - Defense World
Alnylam Pharmaceuticals, Inc to Host Earnings Call - ACCESS Newswire
Alnylam Pharmaceuticals CSO Kevin Fitzgerald sells shares worth $669,303 By Investing.com - Investing.com Australia
Dr. Phillip A. Sharp Retirement From Alnylam Pharmaceuticals (NasdaqGS:ALNY) Board Announced - Simply Wall St
Principal Financial Group Inc. Reduces Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Defense World
Alnylam Announces Retirement of Board Member, Dr. Phillip A. Sharp - citybiz
Alnylam Pharmaceuticals Announces Retirement of Co-Founder Dr. Phillip A. Sharp - GuruFocus.com
Alnylam co-founder Dr. Sharp to retire from board in May - Investing.com India
Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary - Business Wire
Alnylam Pharmaceuticals CEO Yvonne Greenstreet sells $700,893 in stock By Investing.com - Investing.com Australia
Alnylam Pharmaceuticals CEO Yvonne Greenstreet sells $700,893 in stock - Investing.com India
Alnylam Pharmaceuticals CFO sells $192,389 in stock - Investing.com
Alnylam Pharmaceuticals CFO sells $192,389 in stock By Investing.com - Investing.com UK
$1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today - Benzinga
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Alnylam Pharmaceuticals, Inc. (ALNY) - ACCESS Newswire
H.C. Wainwright maintains $500 target on Alnylam stock - Investing.com
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Acquired by Truist Financial Corp - Defense World
Alnylam Pharmaceuticals (NASDAQ:ALNY) Receives "Outperform" Rating from Royal Bank of Canada - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Bought by Allianz Asset Management GmbH - MarketBeat
Proficio Capital Partners LLC Increases Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
National Pension Service Sells 36,876 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Y Intercept Hong Kong Ltd Purchases Shares of 4,516 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Receives Buy Rating from Chardan Capital - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Receives Buy Rating from Needham & Company LLC - MarketBeat
Fjarde AP Fonden Fourth Swedish National Pension Fund Has $6.85 Million Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Los Angeles Capital Management LLC Decreases Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Illinois Municipal Retirement Fund Boosts Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals Inc Stock (ALNY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):